
Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Intrinsic Value
The intrinsic value of one
ADAP
stock under the Base Case scenario is
1.395
USD.
Compared to the current market price of 0.275 USD,
Adaptimmune Therapeutics PLC
is
Undervalued by 80%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Adaptimmune Therapeutics PLC
Fundamental Analysis


Revenue & Expenses Breakdown
Adaptimmune Therapeutics PLC
Balance Sheet Decomposition
Adaptimmune Therapeutics PLC
Current Assets | 103m |
Cash & Short-Term Investments | 59.6m |
Receivables | 20.9m |
Other Current Assets | 22.6m |
Non-Current Assets | 55.1m |
PP&E | 48.9m |
Intangibles | 3.8m |
Other Non-Current Assets | 2.3m |
Free Cash Flow Analysis
Adaptimmune Therapeutics PLC
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Adaptimmune Therapeutics PLC
Revenue
|
179.6m
USD
|
Cost of Revenue
|
-170.1m
USD
|
Gross Profit
|
9.6m
USD
|
Operating Expenses
|
-56.6m
USD
|
Operating Income
|
-47m
USD
|
Other Expenses
|
-22.9m
USD
|
Net Income
|
-69.9m
USD
|
ADAP Profitability Score
Profitability Due Diligence
Adaptimmune Therapeutics PLC's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Score
Adaptimmune Therapeutics PLC's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
ADAP Solvency Score
Solvency Due Diligence
Adaptimmune Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Score
Adaptimmune Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADAP Price Targets Summary
Adaptimmune Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for
ADAP
is 1.74 USD
with a low forecast of 1.01 USD and a high forecast of 3.15 USD.
Dividends
Current shareholder yield for ADAP is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ADAP
stock under the Base Case scenario is
1.395
USD.
Compared to the current market price of 0.275 USD,
Adaptimmune Therapeutics PLC
is
Undervalued by 80%.